Neurosense Therapeutics said it's producing its ALS therapy PrimeC at a commercial scale as it prepares for potential approval in Canada.

NeuroSense Therapeutics provides a comprehensive update on its strategic initiatives and financial outcomes for the first half of 2026, highlighting progress with its ALS therapy, PrimeC.

NeuroSense Therapeutics is set to participate in the 5th Annual ROTH Healthcare Opportunities Conference, discussing key advancements in neurodegenerative disease treatments.

NeuroSense Therapeutics has successfully obtained a crucial patent in South Korea for its innovative drug PrimeC, aimed at treating ALS. This milestone enhances its global patent portfolio and supports further clinical studies.

NeuroSense Therapeutics (NRSN) Chief Financial Officer Or Eisenberg will attend the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026.He will meet with institutional investors in New York City. Expected topics include clinical and regulatory progress with PrimeC, its ALS drug candidate, and the company’s strategy toward potential regulatory approval in Canada, the U.S. and other markets.

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings suggesting target engagement and potential clinical benefits.

NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD 2026 in Copenhagen on March 19, 2026. The presentation reviews Phase 2b PARADIGM findings and biomarker analyses that informed the design of the planned global Phase 3 PARAGON trial.PARADIGM data were recently published in JAMA Neurology, and NeuroSense says it is actively engaging regulators as PARAGON — a multinational, randomized, double-blind, placebo-controlled study — is advanced to further evaluate PrimeC's safety and efficacy.